This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nzila, A.
Right arrow Articles by Ward, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nzila, A.
Right arrow Articles by Ward, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DAPSONE
*PROBENECID

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2108-2112, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2108-2112.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Chemosensitization of Plasmodium falciparum by Probenecid In Vitro

Alexis Nzila,1,2* Eddy Mberu,1 Pat Bray,3 Gilbert Kokwaro,1,2 Peter Winstanley,2 Kevin Marsh,4,5 and Steve Ward3

Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, Nairobi,1 Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Centre for Geographical Medicine Research, Kilifi, Kenya,4 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX,2 Liverpool School of Tropical Medicine, Liverpool L53QA,3 Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom5

Received 20 November 2002/ Returned for modification 28 February 2003/ Accepted 27 March 2003

Resistance to drugs can result from changes in drug transport, and this resistance can sometimes be overcome by a second drug that modifies the transport mechanisms of the cell. This strategy has been exploited to partly reverse resistance to chloroquine in Plasmodium falciparum. Studies with human tumor cells have shown that probenecid can reverse resistance to the antifolate methotrexate, but the potential for reversal of antifolate resistance has not been studied in P. falciparum. In the present study we tested the ability of probenecid to reverse antifolate resistance in P. falciparum in vitro. Probenecid, at concentrations that had no effect on parasite viability alone (50 µM), was shown to increase the sensitivity of a highly resistant parasite isolate to the antifolates pyrimethamine, sulfadoxine, chlorcycloguanil, and dapsone by seven-, five-, three-, and threefold, respectively. The equivalent effects against an antifolate-sensitive isolate were activity enhancements of approximately 3-, 6-, 1.2-, and 19-fold, respectively. Probenecid decreased the level of uptake of radiolabeled folic acid, suggesting a transport-based mechanism linked to folate salvage. When probenecid was tested with chloroquine, it chemosensitized the resistant isolate to chloroquine (i.e., enhanced the activity of chloroquine). This enhancement of activity was associated with increased levels of chloroquine accumulation. In conclusion, we have shown that probenecid can chemosensitize malaria parasites to antifolate compounds via a mechanism linked to reduced folate uptake. Notably, this effect is observed in both folate-sensitive and -resistant parasites. In contrast to the activities of antifolate compounds, the effect of probenecid on chloroquine sensitivity was selective for chloroquine-resistant parasites (patent P407595GB [W. P. Thompson & Co., Liverpool, United Kingdom] has been filed to protect this intellectual property).

* Corresponding author. Mailing address: Wellcome Trust Research Laboratory, P.O. Box 43640, 00100 GPO, Nairobi, Kenya. Phone: 254-2-2710672. Fax: 254-2-2711673. E-mail: anzila{at}wtnairobi.mimcom.net.

Antimicrobial Agents and Chemotherapy, July 2003, p. 2108-2112, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2108-2112.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Masseno, V., Muriithi, S., Nzila, A. (2009). In Vitro Chemosensitization of Plasmodium falciparum to Antimalarials by Verapamil and Probenecid. Antimicrob. Agents Chemother. 53: 3131-3134 [Abstract] [Full Text]  
  • Dahlstrom, S., Veiga, M. I., Martensson, A., Bjorkman, A., Gil, J. P. (2009). Polymorphism in PfMRP1 (Plasmodium falciparum Multidrug Resistance Protein 1) Amino Acid 1466 Associated with Resistance to Sulfadoxine-Pyrimethamine Treatment. Antimicrob. Agents Chemother. 53: 2553-2556 [Abstract] [Full Text]  
  • Nantulya, F. N., Kengeya-Kayondo, J. F., Ogundahunsi, O. A. T. (2007). Research Themes and Advances in Malaria Research Capacity Made by the Multilateral Initiative on Malaria. Am J Trop Med Hyg 77: 303-313 [Abstract] [Full Text]  
  • Tahar, R., Basco, L. K. (2007). Molecular Epidemiology of Malaria in Cameroon. XXVI. Twelve-Year In Vitro and Molecular Surveillance of Pyrimethamine Resistance and Experimental Studies to Modulate Pyrimethamine Resistance. Am J Trop Med Hyg 77: 221-227 [Abstract] [Full Text]  
  • Nzila, A. (2006). The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 57: 1043-1054 [Abstract] [Full Text]  
  • DZINJALAMALA, F. K., MACHESO, A., KUBLIN, J. G., TAYLOR, T. E., BARNES, K. I., MOLYNEUX, M. E., PLOWE, C. V., SMITH, P. J. (2005). BLOOD FOLATE CONCENTRATIONS AND IN VIVO SULFADOXINE-PYRIMETHAMINE FAILURE IN MALAWIAN CHILDREN WITH UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA. Am J Trop Med Hyg 72: 267-272 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»